Ibrutinib is safer than we think

Ibrutinib works, but does using it set patients up for potential relapse by causing increased genomic instability? This question is addressed in this issue of Blood by Morande et al, who provide convincing evidence that resolves a key safety issue surrounding the use of this drug, giving new insight into its mechanism of action.(1)